QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Latest DehydraTECH-CBD Study May Be 1st to Evidence Sustained Drop in Blood Pressure
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs, has, since inception, been committed to addressing severe unmet patient needs. Hypertension has been one of its main focus areas. “Lexaria continues to move forward, most recently with the success in its latest human clinical study, HYPER-H21-4. The study may be the first to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (‘CBD’) therapy using the company’s patented DehydraTECH(TM) technology,” reads a recent article. “Since Lexaria began developing DehydraTECH…